58 results about "Serology" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine in evaluating Kawasaki disease and treating effect thereof and application of a phenylalanine inhibitor in treating Kawasaki disease. According to serum non-targeted metabonomics analysis and verification of KD children and IVIG treated KD children, phenylalanine is highly expressed in KD children, and phenylalanine is remarkably reduced after IVIG treatment of KD and tends to healthy children. The phenylalanine can be used as a serological marker for evaluating the Kawasaki disease treatment effect and diagnosing IVIG second-line treatment, and is high in specificity and sensitivity. After the phenylalanine inhibitor is administered to a KD model mouse, the content of phenylalanine in serum is remarkably reduced and is consistent with the trend in serum of the KD mouse treated by IVIG, myrica tongues are remarkably relieved, arterial dilatation is slowed down, and expression of inflammatory factors is reduced. The phenylalanine inhibitor has the effects of treating Kawasaki disease, improving myrica rubra tongue and slowing down arterial dilatation.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

The application belongs to the field of biotechnology detection, and particularly relates to a multiplex PCR detection kit for identifying and distinguishing chicken pullorum salmonella and chicken typhoid salmonella. The kit comprises stn gene detection primers, I137_14445 gene detection primers and ybgL gene detection primers. The kit can quickly, high-throughput and accurately identify and distinguish chicken pullorum salmonella and chicken typhoid salmonella, can replace traditional salmonella serological typing and biochemical identification and other complex procedures, and provides a simple, rapid, reproducible new method for monitoring and laboratory diagnosis of chicken pullorum salmonella and chicken typhoid salmonella.

This invention relates to the field of biotechnology, and aims to provide a monoclonal antibody 7A12 for identifying genotype 2 classical swine fever, along with its preparation and application methods. This monoclonal antibody contains an Ig domain V of the antibody heavy chain. H CDR1, V H CDR2 and V H CDR3, and the Ig domain V of the antibody light chain L CDR1, V L CDR2 and V L CDR3; wherein, the V H CDR1, V H CDR2 and V H The amino acid sequences of CDR3 are shown in SEQ ID NO:1-3, respectively; the V L CDR1, V L CDR2 and V L The amino acid sequences of CDR3 are shown in SEQ ID NO:4-6. The antibody provided by this invention has advantages such as high titer, strong specificity, and high affinity; it also has high sensitivity and specificity, and shows no cross-reactivity with type 1 classical swine fever vaccine strains. Serologically, it can differentiate and diagnose infection and vaccine immunization with genotype 2 classical swine fever wild-type strains. Furthermore, it can be used to develop a blocking ELISA kit for identifying genotype 2 classical swine fever, effectively diagnosing and purifying genotype 2 classical swine fever virus.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The application discloses application of a reagent for detecting a biomarker in preparation of a product for predicting ulcerative colitis disease activity or a product for diagnosing ulcerative colitis disease, and relates to the technical field of serological markers of inflammatory bowel disease. The serum CD105 of a UC patient is significantly higher than that of a healthy control group, and CD105 has a very high effect of diagnosing ulcerative colitis disease, and CD105 can distinguish disease activity from remission. Therefore, the application provides a novel serum marker which is convenient to sample, has good repeatability and can objectively reflect the colon mucosa inflammation load, and is expected to provide more accurate marker selection for UC disease activity prediction and UC diagnosis.

The present application relates to the technical field of medical data mining, in particular to a whole-course management system based on fusion analysis of hepatitis B serological and virological indexes, which comprises a serum index collection module, an evolution path construction module, a characteristic section extraction module, an intervention response classification module and a fusion structure induction module.In the present application, based on the index sequence matrix formed by continuous sampling, the trend trajectory is generated by tracking the change direction of the index concentration at each time node, the change fragments with structural differences are extracted in combination with the biochemical response markers, the index combination relationship under different interventions is classified and arranged, the matching mapping between the intervention behavior and the response path is established, the regular characteristics of the intervention effect are reflected through the combination of multiple indexes, and then the induction analysis result set covering the whole treatment process is generated, thereby providing clear data basis for dynamic intervention evaluation and treatment path adjustment.

The invention discloses an osteonecrosis early diagnosis kit based on blood detection and a biomarker, and the osteonecrosis early diagnosis kit can be used for early diagnosis of osteonecrosis through multi-omics screening based on femoral head necrosis lesion division, serological analysis of different stages of cases and cell and animal level biological tests in combination with actual detection result verification. It is determined that a group of biomolecules, namely PEBP1, ACAT1, MMP2, SOD1 and FN1 proteins, can be used for early diagnosis of osteonecrosis.

The invention belongs to the technical field of biology, and particularly relates to a bispecific antibody targeting African swine fever virus and hog cholera virus and application of the bispecific antibody, the bispecific antibody shows high binding capacity to p30 protein of the African swine fever virus and E2 protein of the hog cholera virus, and it is indicated that the bispecific antibody can recognize the African swine fever virus and the hog cholera virus at the same time. When the bispecific antibody disclosed by the invention is used for preparing a detection product, double-flux detection of screening African swine fever viruses and swine fever viruses can be realized at the same time through one-time detection, and a new thought is provided for multiple detection of swine disease serology.

The application relates to an AI-assisted result interpretation micro-sample detection kit for cutaneous leishmaniasis infection and an antibody detection method, and belongs to the technical field of serological immunodetection. The kit comprises an antibody detection platform for micro-samples, micro-bead probes, a washing solution, an antibody diluent, F594-labeled sheep anti-rat antibodies, positive quality control serum and negative quality control serum; the spherical probes are adopted in the application, the antigen-antibody combination efficiency is improved in space, and the antigen-antibody collision probability is effectively improved. Meanwhile, the micro-beads form a micro-scale mass transfer network in the reaction cavity, fluid mixing is enhanced, the reaction time is shortened, and the overall residence time and consumption of samples and reagents in the microfluidic channel are reduced. The application also introduces an AI-assisted result interpretation system to assist in result interpretation, significantly improves the friendliness and accessibility of the detection process, the classification model based on artificial intelligence has stronger robustness and judgment consistency, and has good market development value and popularization and application prospect.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

This invention discloses a risk prediction device and storage medium for metabolic-associated fatty liver disease in children or adolescents. The two-stage cascaded screening strategy and model of this invention provide a highly accurate, accessible, and scalable solution for the early identification of metabolic-associated fatty liver disease in children or adolescents. This invention utilizes different anthropometric data to identify high-risk groups in routine school physical examinations, followed by further screening using a comprehensive serological index at community health centers, thereby achieving accurate diagnosis of metabolic-associated fatty liver disease and providing clinicians with a non-invasive auxiliary diagnostic tool that combines high precision, high accuracy, and broad accessibility.

The invention provides a Hunipah virus mRNA vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The mRNA vaccine provided by the invention comprises mRNA attached to glycoprotein of a full-length Hendea virus and an mRNA vaccine delivery system, and serological analysis and a Nipah virus-Malaysia strain and Hendea virus challenge protection experiment prove that the vaccine provided by the invention can generate a very good immune protection effect only by immunizing two doses; the mRNA vaccine has effectiveness on a Nipah virus-Malaysia strain and a Hendea virus at the same time, can protect a subject from lethal infection of the Nipah virus-Malaysia strain and the Hendea virus, and is good in broad spectrum.

The invention relates to the technical field of antibodies, and particularly provides an antibody specifically bound with African swine fever virus p34 protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO.1 and a light chain variable region as shown in SEQ ID NO.3, and the antibody or the antigen binding fragment thereof can recognize ASFV p34 protein with high specificity. The invention also provides a nucleic acid molecule for coding the antibody or the antigen binding fragment thereof, an expression vector, a recombinant cell and other biological materials. The antibody or the antigen binding fragment thereof can be used for preparing an African swine fever virus detection product, particularly a blocking ELISA antibody detection kit, and the kit has the advantages of high sensitivity, strong specificity, simplicity and convenience in operation and the like, and is suitable for serological monitoring and diagnosis of ASFV. The invention provides an effective detection tool for prevention and control of African swine fever.

The invention discloses a salmonella H: i epitope specific monoclonal antibody and application thereof, the salmonella H: i epitope specific monoclonal antibody is secreted by hybridoma cells with the preservation number of CCTCC NO: C202645, and the antibody has the advantages of high titer and strong specificity. According to the blocking ELISA detection kit constructed by the antibody and the detection method of the blocking ELISA detection kit, the antibody containing H: i antigen epitope salmonella in infected animal serum can be specifically detected, the antibody does not react with antibodies containing no H: i antigen epitope salmonella and non-salmonella, the sensitivity, specificity and stability are good, and the detection method is simple and convenient. And a new method is provided for direct serological detection of H: i antigen epitope-containing salmonella infection of mouse typhimurium, kafenkii and the like.

The invention discloses a blood group reagent quality control kit and application thereof, the blood group reagent quality control kit comprises a plurality of independently subpackaged composite quality control products, and each quality control product simultaneously comprises quality control red blood cells with known antigen spectra and quality control plasma with known antibody spectra; the quality control red blood cells are human red blood cells with known ABO blood type, RhD blood type and Rh haplotype; the quality control plasma contains blood group antibodies with known specificity and immune globulin types, and the blood group antibodies comprise IgM antibodies and / or IgG antibodies. The invention also discloses application of the blood group reagent quality control kit in indoor quality control of blood group serology detection and an indoor quality control method of blood group serology detection. The kit provided by the invention can realize integrated and efficient detection, and synchronously complete indoor quality control of a plurality of core items such as blood type identification, antibody screening, cross matching of blood and the like.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

The invention discloses a B cell epitope peptide based on human papilloma virus E6 protein and application of the B cell epitope peptide in cancer diagnosis. According to the invention, the epitope peptide is displayed and expressed on the surface of an inert carrier bacterium S9H, so that an RI5 epitope peptide-antibody direct mediated agglutination test detection system based on thallus surface epitope display is successfully constructed. Compared with an immunoserological detection technology based on a complete protein antigen, the kit provided by the invention can be used for more specifically, sensitively, conveniently and quickly detecting the virus oncoprotein specific antibody in the body of an HPV persistent infection patient, and can be used for qualitatively and quantitatively determining the content of the antibody. The epitope peptide-antibody direct mediation agglutination test detection technology provides an efficient and reliable new method for accurate diagnosis of dynamic changes of virus oncoprotein antibodies in persistent infection and cancer stages of HPV patients, and has potential important clinical application value.

FIELD: biotechnology.SUBSTANCE: concerns a new strain of bacteria Campylobacter jejuni / 723 of the family Campylobacteriасеае of the genus Campylobacter species C. jejuni, deposited in the All-Russian State Collection of Exotic Types of Foot-and-Mouth Disease Viruses and Other Animal Pathogens (GKSHM) of the FSBI ARRIAH under the registration No. 723-dep / 24-GKSHM of the FSBI ARRIAH. The proposed strain grows on Columbia agar with the addition of 5% defibrinated ram blood; the strain possesses pronounced properties characteristic of its species.EFFECT: presented strain can be used in the development and production of components (antigen and serum) for serological reactions for the diagnosis of campylobacteriosis in farm animals and as a positive control for the identification of bacteria of the genus Campylobacter by real-time PCR and the identification of the species Campylobacter jejuni by time-of-flight mass spectrometry.1 cl, 3 dwgs, 3 tbls, 5 ex

The application discloses a blocking agent for milk allergen component-specific IgE antibody test strips and application, and belongs to the technical field of immune detection and analysis. The blocking agent uses soybean protein isolate and fish gelatin as the blocking agent in antigen-antibody reaction of immunoserological technology, so as to reduce false negative results caused by using conventional blocking agents, casein and bovine serum albumin, and thus makes the detection result more accurate.

The application discloses a multiplex PCR detection system, a kit and application for RH gene typing detection. The application can efficiently and accurately identify common Rh genotypes in Asian population through a single PCR amplification reaction. The application not only effectively makes up for the limitations of traditional serological methods in detecting complex blood types such as D variant, but also has the advantages of high standardization, low cost, simple operation and low clinical promotion threshold.

The application discloses peripheral blood CD8 + The application discloses an application of T cell absolute count as a biomarker in prevention or evaluation of pulmonary lymphangioleiomyomatosis. The application breaks the limitation of traditional methods mainly depending on imaging or single serological index, provides a novel diagnosis strategy based on peripheral blood immune cell absolute count, is convenient for sampling (venous blood can be drawn), has low detection cost, can be used for dynamic monitoring of patient's disease severity and prognosis stratification, and lays a solid foundation for subsequent development of immune regulation target drugs for S-LAM.

The invention discloses a cardiovascular event risk index calculation method, and relates to the technical field of medical information, and the method comprises the following steps: determining whether a to-be-evaluated patient meets an application condition or not according to a preset inclusion standard; for a patient meeting the standard, collecting a peripheral blood sample of the patient, carrying out centrifugal treatment, and separating to obtain a serum or plasma sample; s2, quantitatively measuring four serological indexes, namely lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, homocysteine and serum amyloid protein A, of the serum or plasma sample obtained in the step S1 by using an authenticated laboratory detection method; s2, calculating a cardiovascular risk index by using a cardiovascular risk calculation formula based on the four index values measured in the step S2; s3, according to the cardiovascular risk index value calculated in the step S3, dividing the cardiovascular event risk of the patient into three levels of low risk, medium risk and high risk; and S4, generating a structured risk assessment report according to the risk grading result obtained in the step S4, and outputting the structured risk assessment report.

The invention belongs to the technical field of animal model construction, and discloses a construction method and application of an animal model with hyperuricemia spleen deficiency and damp turbidity retention syndrome. According to the method, on the basis that a hyperuricemia model mouse is prepared through chemical induction or gene editing, the hyperuricemia model mouse conforming to the pathogenesis of spleen deficiency and damp turbidity in traditional Chinese medicine is constructed through combination of high fat diet and weight-bearing exhaustive swimming, model evaluation is conducted through disease-related indexes, histopathologic indexes and serologic indexes, and the hyperuricemia model mouse with the spleen deficiency and damp turbidity in the traditional Chinese medicine pathogenesis is obtained. The invention aims to provide a reliable experimental carrier for research and development of hyperuricemia drugs and research of drug action mechanisms. Based on the characteristics of clinical traditional Chinese and western medicine symptoms, the animal model which not only meets the modern medical diagnosis standard of hyperuricemia, but also fully embodies the characteristics of damp turbidity accumulation syndromes is planned to be established. The model not only can be used for screening and evaluating the traditional Chinese medicine compound with the uric acid reducing effect, but also can be used for deeply researching the mechanisms of regulating metabolism, inhibiting inflammation and the like of the spleen invigorating and dampness eliminating treatment method.

The invention relates to a non-invasive early warning method for autoimmune gastritis. The method comprises the following steps: acquiring serological indexes, basic information indexes, symptom characteristics and past medical history; determining serum risk points, basic risk points, symptom risk points and disease risk points according to serological indexes, basic information indexes, symptom characteristics and past medical history; and evaluating the AIG disease risk according to the serum risk integral, the basic risk integral, the symptom risk integral and the disease risk integral. The problems that in the prior art, the AIG disease risk cannot be evaluated in time through a non-invasive detection means, the evaluation efficiency cannot be improved, the evaluation cost cannot be reduced, and the evaluation accuracy cannot be improved are solved.

This invention relates to the field of molecular biology, specifically to a nested PCR primer set, kit, and application for detecting porcine infectious pleuropneumonia. The kit, developed by establishing a nested PCR amplification primer set, can be used for the in vitro diagnosis of porcine infectious pleuropneumonia. It exhibits high sensitivity, detecting up to 0.355 pg / µL, which is nearly 100 times higher than that of conventional PCR (35.5 pg / µL). It also demonstrates strong specificity, overcoming the problems of low sensitivity and poor specificity associated with conventional PCR. Compared to existing indirect immunofluorescence and serological detection methods, it offers lower cost and a shorter detection cycle.

The invention belongs to the technical field of medicine, and discloses an application method of CLIC3 as a serological molecular marker in prediction of lung cancer bone metastasis, CLIC3 is significantly increased in serum of patients with lung cancer bone metastasis, and the total lifetime and non-metastasis lifetime of lung cancer patients with high expression of CLIC3 are significantly shorter than those of patients with low expression. In addition, bone metastasis in a mouse model constructed by CLIC3 high-expression lung cancer cells is remarkably enhanced. Based on detection and analysis of clinical specimens, it is successfully identified that CLIC3 can serve as a brand new serum marker and has a key indication effect in the aspect of early warning of lung cancer bone metastasis. In the research process, multi-dimensional verification is carried out by comprehensively applying a bioinformatics technology, molecular biology detection, a mouse animal model and other methods, and the serum CLIC3 has outstanding potential early warning efficiency and is expected to serve as a novel biological marker with innovativeness, scientificity and clinical application prospects in the early warning category of lung cancer bone metastasis.

Methods and compositions are provided for the detection of HPV infection in a subject sample. In particular, the methods and composition include variants of certain HPV proteins (e.g., HPV16 E6 protein), wherein the HPV proteins have been modified to enhance solubility while maintaining or enhancing seropositivity to HPV positive plasma / sera. Additional methods and compositions relate to improving purification of HPV proteins through the use of modified amino acid sequences. These approaches may enhance the performance of serological detection techniques and support broader implementation of detection assays.

The invention relates to the technical field of biology. Specifically, the invention discloses a protein chip, a kit and application thereof. The protein chip comprises a substrate, 44 first antigens and 11 second antigens, wherein the 44 first antigens and the 11 second antigens are connected with the substrate; the first antigen is antigen protein, and the second antigen is polypeptide. The protein chip provided by the invention can realize bovine disease serological high-throughput detection and rapid bovine disease screening.

In this invention, the inventors report the characterization of BCLA (brain cyst-loaded antigen), a protein uniquely expressed in the merozoite stage of a parasite. In cysts directly purified from mouse brain, the protein is distributed both internally and on the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptide and recombinantly expressed C-terminal domain (rBCLA) constitutes an effective serological marker of latent infection with high sensitivity, definitively and uniquely correlated with the presence of cysts in mouse brain. Antibodies against the BCLA antigen have been detected in human patients. Enrichment titers were detected in patients identified as seropositive for Sag1 or tachyzoite-associated antigen. Further correlation between anti-BCLA IgG synthesis and cysts in humans was demonstrated by significantly stronger recorded titers in the pathology group strongly correlated with the presence of cysts. Furthermore, newborns with confirmed congenital toxoplasmosis showed significantly higher levels of anti-BCLA IgG at birth compared to their mothers, indicating specific intrauterine synthesis of this IgG. Therefore, this invention relates to a novel Toxoplasma gondii protein, hereinafter referred to as BCLA, which is a novel serological marker whose expression is limited to latent toxoplasmosis (schizonts / cysts). This specific protein and its antigenic fragments can be used to detect autoantibodies in patient serum for the diagnosis of latent toxoplasmosis. This invention also relates to derived antibodies that specifically bind to this novel protein, generated through immunization with BCLA.